Please ensure Javascript is enabled for purposes of website accessibility

Why Immunovant Stock Dropped Today

By Prosper Junior Bakiny - Feb 2, 2021 at 3:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is pausing one of its clinical studies.

What happened?

Shares of Immunovant (IMVT -1.03%), a clinical-stage biopharmaceutical company, were down by 43.2% as of 2:57 p.m. EST on Tuesday, after plunging by as much as 48% earlier in the day. The losses came after Immunovant announced an update regarding one of its ongoing clinical trials.

So what

Immunovant is developing IMVT-1401 for the treatment of several conditions, including thyroid eye disease (TED). During a phase 2b clinical trial, Immunovant recorded cases of elevated total cholesterol and LDL levels in patients treated with IMVT-1401. LDL stands for low-density lipoprotein, and it is a form of cholesterol.

High levels of LDL can lead to severe health consequences, including heart attack and stroke. Immunovant said that based on preliminary data on 40 patients, mean LDL levels increased by about 65% in the 680mg dose group after 12 weeks, and mean LDL levels in the 340mg dose group increased by about 40% in the same period. Mean LDL levels did not increase in the placebo group after 12 weeks.

Road sign that says "risk ahead."

Image source: Getty Images.

However, the company also noted that at the 20-week mark, average LDL levels had dropped to baseline or lower in all three groups. According to Immunovant, there were no serious cardiovascular events reported during the trial. Immunovant decided to pause the study and inform all concerned parties (including patients and regulators). The company's decision to put the study on hold and the reason why it (wisely) chose to do so explain its stock price falling off a cliff today.

Now what

The market doesn't like uncertainty, and while we don't know for sure whether the higher LDL observed in patients taking IMVT-1401 after 12 weeks was due to the experimental medicine, today's news was enough to scare off investors. And considering IMVT-1401 is Immunovant's only pipeline candidate at the moment (the company has no products on the market), staying far away from this healthcare stock seems like the right move. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunovant, Inc. Stock Quote
Immunovant, Inc.
$3.84 (-1.03%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.